

# ESMO 2021 Industry Satellite Symposium

Monday 20th September 2021

18:45–20:15 CEST

Channel 3


## Mapping pathways for PARP inhibition in prostate cancer: practical considerations for clinical practice

Chairperson and speaker



**Fred Saad, MD, FRCS**  
University of Montreal Hospital Center (CHUM), Montreal, Canada

Speaker



**Joaquin Mateo, MD, PhD**  
Vall d'Hebron Institute of Oncology, Barcelona, Spain

Speaker



**Andrew Armstrong, MD, MSc, FACP**  
Duke Cancer Institute, Durham, NC, USA

### Agenda

Welcome and introduction

Fred Saad

Perspectives on the current management of metastatic castration-resistant prostate cancer

Fred Saad

Evaluating the clinical data and evolving landscape for PARP inhibitors in metastatic castration-resistant prostate cancer

Joaquin Mateo

Practical considerations for testing for HRRm in advanced prostate cancer

Andrew Armstrong

Panel discussion: Real-world management of patients with prostate cancer considered for PARP inhibitor treatment

Fred Saad  
Andrew Armstrong  
Joaquin Mateo

### Live Q&A

Join the discussion on Monday 20th September 2021  
15-minute Q&A

AstraZeneca 

This industry session is organised and sponsored by AstraZeneca; it is a non-promotional, peer-to-peer scientific exchange meeting to allow healthcare professionals to discuss the current scientific evidence and evolving approaches in the medical management of metastatic castration-resistant prostate cancer.

This industry session may contain information about investigational products and investigational uses which are not yet approved in the EU

Veeva ID: CH-4380  
Date of preparation: July 2021